TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05520242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of small animation movies to increase response in a national health survey
Description: Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of small animation movies to increase response in a national health survey
Description: Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of small animation movies to increase response in a national health survey
Description: Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of small animation movies to increase response in a national health survey
Description: Inclusion of animation movies in the invitation cover letter to a national health survey is tested in an embedded randomized controlled trial in the Danish National Health Survey 2021.
Study: NCT05778643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TaKeTiNa music therapy
Description: TaKeTiNa music therapy uses a group to perform music together. Each member of the group is needed for the synchronization of the whole group. The group actively makes Music with hands, feet, and the voice. At the same time, the therapist frequently introduces new elements into the process and challenges the group in this playful manner. Through this, patients consistently report an increase in mindful awareness and an alleviation of many depressive symptoms, although these effects have not been shown in controlled studies yet.
Study: NCT04322695

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rehabilitation Education Care Program
Description: The RECP contained the following domains: (1) assessment and detection of disability; (2) home exercise; (3) activities to improve mobility; (4) dietary management; (5) patient education; and (6) vocational counseling.
Study: NCT06028737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 50mg/m2, d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks
Study: NCT05509244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 1g iv dripping at end of surgery
Study: NCT06028737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study: NCT05628688

Intervention type: DIAGNOSTIC_TEST
Intervention: Insight Pro Device for Diagnosis
Description: Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: Insight Pro Device for Diagnosis
Description: Insight Pro Device for Diagnosis of Lymphatic and Venous Disorders
Study: NCT06028737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study: NCT05509244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 300mg iv dripping at end of surgery
Study: NCT06028737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study: NCT05925855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US with fastum
Description: apply fastum on trigger point with US

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US with reparil
Description: apply reparil on trigger point with US

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US with plain gel
Description: apply gel on trigger point with US
Study: NCT05381168

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium from fish bone
Description: Calcium from fish bone contained calcium 312 mg and vitamin D 100 IU per capsule.
Study: NCT05558345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
Study: NCT05381168

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Calcium carbonate contained calcium 600 mg and vitamin D 200 IU per capsule.
Study: NCT04801693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479
Study: NCT05954728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR)
Description: CBT-AR is a four-stage modular treatment for ARFID delivered by a mental health clinician. The four stages include: 1) Psychoeducation and early change; 2) Treatment planning; 3) Addressing maintaining mechanisms; and 4) Relapse prevention. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling for Avoidant/Restrictive Food Intake Disorder
Description: Nutrition counseling will be provided by skilled registered dietitians at the MGH Translational and Clinical Research Center (TCRC). Sessions focus on the foods necessary for a healthy diet, how to meet nutritional needs, how to incorporate healthy exercise, and support for making these changes. For participants ages 10-15 years, patients/guardians attend the sessions. For patients ages 16 and up, the therapy is individual.
Study: NCT06442241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 low dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Study: NCT04801693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06442241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 low dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 middle dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 middle dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 high dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 high dose without adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 low dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 low dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 middle dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 middle dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 high dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB005 high dose with adjuvant
Description: Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
Study: NCT06289725

Intervention type: DRUG
Intervention: antiviral treatment
Description: The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019

Intervention type: DRUG
Intervention: antiviral treatment
Description: The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
Study: NCT06480825

Intervention type: OTHER
Intervention: Performance of ultrasonographic scan
Description: Ultra-high frequency ultrasonographic scan of gingival tissues

Intervention type: OTHER
Intervention: Performance of ultrasonographic scan
Description: Ultra-high frequency ultrasonographic scan of gingival tissues
Study: NCT05081934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CRA
Description: 12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
Study: NCT05935605

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE)
Description: Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE)
Description: Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE)
Description: Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiography (TTE)
Description: Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
Study: NCT04952727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study: NCT05200741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DelNS1-2019-nCoV-RBD-OPT1
Description: Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Solution for Intranasal Spray
Study: NCT06418464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AP-A Dosage Decision Support System
Description: The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AP-A Dosage Decision Support System
Description: The AP-A Dosage Decision Support System represents a new solution in diabetes care, offering customized insulin dosage recommendations to patients. This system is a product of integrating four pivotal modules: the individualized model learning module, the risk-sensitive control module, the Bayesian optimization module, and the safety constraint module. Together, they establish a robust framework that employs advanced computational methodologies to deliver precise and personalized insulin dosage guidance, significantly improving the effectiveness and safety of diabetes treatment plans. The actual injection dose in the intervention group was executed by the doctor after approval based on the recommendation of the AP-A Dosage Decision Support System.
Study: NCT05521776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First-trimester preeclampsia screening (FMF triple test)
Description: An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered.
Study: NCT04985396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) group
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP) group
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
Study: NCT06293092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leg pedaling cycling device
Description: Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sand bags
Description: Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis sessions
Description: hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis sessions
Description: hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemodialysis sessions
Description: hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
Study: NCT05763316

Intervention type: OTHER
Intervention: CRIB II
Description: Calculate Clinical Risk Index for Babies II score
Study: NCT04962945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oblique-axis approach group
Description: The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis approach group
Description: The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
Study: NCT06596018

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Target the primary tumor region with a single dose of 8Gy using 6MV-X rays, administered once a day for three consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）